Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer

BABACAN T., Efe O., Hasirci A. S., Demirci F., Buyukhatipoglu H., Balakan O., ...More

TUMORI J, vol.101, no.4, pp.418-423, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 101 Issue: 4
  • Publication Date: 2015
  • Doi Number: 10.5301/tj.5000332
  • Journal Name: TUMORI J
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.418-423
  • Hacettepe University Affiliated: Yes


Aims and Background: Capecitabine is a potent and safe agent that can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of capecitabine monotherapy as a first-line treatment in human epidermal receptor 2 (HER2)-negative patients with MBC.